The Last Plaque short film is now live
The new and stylish short film, “The Last Plaque,” sponsored by the nonprofit Psoriasis Cure Now (that’s us!), debuted on World Psoriasis Day, October 29, 2021. The film asks: “What happens when the world is finally free from plaque psoriasis?” We would also ask: “What would the end of psoriasis Continue Reading…
COVID-19, vaccination, and psoriasis: the latest in what you need to know
Despite our best hopes, COVID is still with us, and now vaccination news and debates confront us wherever we turn, from the internet to the local convenience store. For people with psoriasis and/or psoriatic arthritis, it raises many questions, as we try to balance potential risks from the coronavirus with Continue Reading…
COVID vaccine hesitancy in psoriasis patients not necessary, experts say
A study reviewed social media posts of psoriasis and/or psoriatic arthritis patients in the US and four European countries to learn the top reasons for COVID vaccine hesitancy among those who are hesitant and using biologics to treat their psoriatic disease. The most commonly cited concerns, it turns out, have Continue Reading…
Psoriasis … hard to forget
This is not exactly essential news, but we wanted to pass it along. MedPage Today reported on, and interviewed the author of, a study that found: People who answered in a questionnaire that they had previously had psoriasis, pretty much said the same thing two years later. Of course, that Continue Reading…
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…
Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…
Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis
AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and the new biologic Skyrizi (risankizumab-rzaa), has asked the U.S. Food and Drug Administration (FDA) and its European counterpart to approve its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for psoriatic arthritis. Rinvoq is a JAK inhibitor administered as Continue Reading…
Our new “Psoriasis Journey” campaign is rolling out
Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…
Want to try an experimental psoriasis treatment for your skin or scalp?
Before a doctor can prescribe a treatment, it goes through years of research and testing, including multiple rounds of clinical trials, using volunteer patients to test a potential treatment’s safety and effectiveness. The clinical trials are developed in consultation with government regulators (here, the US Food and Drug Administration, or Continue Reading…